Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 9,959 shares, a decline of 59.9% from the May 31st total of 24,832 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 31,504 shares, the short-interest ratio is presently 0.3 days.

Pulmatrix Stock Down 1.8%

NASDAQ PULM traded down $0.03 during trading hours on Monday, hitting $1.61. 19,781 shares of the stock were exchanged, compared to its average volume of 49,545. The company has a market cap of $5.88 million, a price-to-earnings ratio of -1.31 and a beta of 1.95. Pulmatrix has a 12-month low of $1.16 and a 12-month high of $7.20. The stock has a 50-day moving average of $1.36 and a 200 day moving average of $2.03.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is owned by institutional investors and hedge funds.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).